Denali Therapeutics amends bylaws for universal proxy and Delaware law updates

Denali Therapeutics Inc.

Board approved amended restated bylaws effective November 12, 2024.
Updates advance notice procedures for director nominations and stockholder proposals.
Requires stockholder to show Rule 14a-19 compliance 5 business days before meeting.
Conforms provisions to current Delaware General Corporation Law.
Updates provisions on directors, board committees, officers, and ministerial changes.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Denali Therapeutics Inc.: Amended and restated bylaws to update advance notice procedures, conform to universal proxy rules, and align with Delaware law, effective upon approval (effective 2024-11-12).

Change: bylaw amendment
Effective: 2024-11-12

Exact text from the filing

On November 12, 2024, the Board of Directors (the “ Board ”) of Denali Therapeutics Inc. (the “ Company ”), acting upon the recommendation of the Board’s Corporate Governance and Nominating Committee, approved and adopted amended and restated bylaws (as so amended and restated, the “ Amended and Restated Bylaws ”), which became effective upon such approval and adoption.

View on SEC.gov

Browse all governance changes →

Denali Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001714899-24-000233

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.